Recent Updates
Recently added Catalysts
OVID Positive Sentiment

Northwestern University

Friday, September 22, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Ovid has entered a licensing agreement with Northwestern University for OV329, granting them exclusive rights to research and commercialize the drug. The company is investigating OV329's potential in treating various treatment-resistant epilepsies, including those associated with Tuberous Sclerosis Complex and Infantile Spasms.
Price reaction · baseline $3.515 (2023-09-22T16:09:00.000Z) · hit during market hours · 26 other OVID headline(s) in the window, move may be shared
day 0 close · peak
+3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ovid has secured an exclusive license for OV329.
  • The drug is aimed at treatment-resistant epilepsies.
  • OV329 may benefit patients with Tuberous Sclerosis Complex.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+622%
120-day peak, hindsight
Typical move
2.4%
average across 3 past catalysts
Cash runway
~33 mo
Minimal dilution risk

Full Press Release Details

In December 2016, Ovid entered into a license agreement with Northwestern University that granted Ovid an exclusive, worldwide license to research, develop, manufacture, and commercialize OV329. Ovid is exploring the potential benefits of OV329 in a number of treatment-resistant epilepsies, including for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms.

Frequently Asked Questions

What is OV329?

OV329 is a drug developed by Ovid for treatment-resistant epilepsies.

Who licensed OV329 to Ovid?

Ovid licensed OV329 from Northwestern University.

What conditions is OV329 targeting?

OV329 is aimed at treating Tuberous Sclerosis Complex and Infantile Spasms.

When was the licensing agreement made?

The licensing agreement was established in December 2016.

ShareAdd on Google
Tags: OVID Viatris Investor Conferences Healthcare Ovid OV329 Northwestern University epilepsy Tuberous Sclerosis Complex
Last updated: Sep 22, 2023

Biotech snapshot

Cash runway
$166M liquidity · $5M/mo burn
~33 mo
Minimal dilution risk

Catalyst track record

+622%
best trade around OVID's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for OVID.

See every catalyst's timing & PoA →